Genmab starts Phase II study of HuMax-EGFr antibody in new indication
Forbes - COPENHAGEN (Thomson Financial) - Genmab AS said it has initiated a Phase II study of its fully human antibody HuMax-EGFr (zalutumumab) in combination with chemo-radiation to treat non-small-cell lung cancer (NSCLC). The objective of the study, which
Genentech Net Soars on Cancer, Eye Drugs
Smart Money - The drug was recently approved to treat lung cancer in addition to colorectal cancer. Rituxan, which is used to treat non-Hodgkin’s lymphoma, had sales rise 12% to $535 million, while breast-cancer treatment Herceptin’s sales rose 7%. Herceptin drug
Christopher Reeve’s chair snub
Boston Globe - Deborah Morosini, the sister of Christopher’s late wife, Dana - who died of lung cancer in 2005 - said she had offered the institution the chair, but was upset by the additional requests. The other items the museum asked for included Christopher’s
Ahead of the Bell: Cyclacel Rises
Forbes - Its lung cancer drug seliciclib is in mid-stage testing, he said, and could be approved in 2011, helping the company turn a profit in 2012. The Berkeley Heights, N.J.-based company has at least eight drugs in preclinical or early testing, Zavoico said
The Longest Duesenberg
BusinessWeek - He died of lung cancer in November 1953 at 64, and his widow soon advertised the car. Bill Pettit purchased it and stored it at his Museum of Motoring Memories in Virginia for 45 years, preserving it in pristine, untouched condition. Pettit drove it
Former Winston Man says don t believe tobacco companies
Seneca County Advertiser-Tribune - April Carpenter, an eighth-grader at Carey Junior High School and niece of Beth Gabriel, public information officer for the Wyandot County Health Department, said the message about the potential of lung cancer stuck out in her mind. I enjoyed all
Premarket Movers: Same-store sales
Boston Globe - Shares of biopharmaceutical company Cell Therapeutics jumped 13 percent Wednesday, after the Food and Drug Administration fast-tracked its lung cancer drug candidate Xyotax. Cell Therapeutics shares fell 19 cents, or 10.4 percent, to $1.64 in heavy